The discovery and development of an efficient, practical asymmetric synthesis of the HIV Protease inhibitor CRIXIVAN® is described. Particular emphasis is placed on the selective installation of each of the five stereogenic centers as well as design strategies associated with the preparation of a complex pharmaceutical agent needed in multiton quantities.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Dec 1 1997|
All Science Journal Classification (ASJC) codes